To elucidate how FGFR4 confers anti-HER2 resistance in breast cancer, we performed RNA next-generation sequencing in FGFR4-suppressed and control rSKBR3 cells (Fig. 4a). This evidence concerns the gene ERBB2 and breast carcinoma.